Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

M. Nielsen Hobbs

Executive Editor

Washington DC
M. Nielsen Hobbs has more than 20 years of experience covering the pharmaceutical industry, and writes frequently about the intersection of business, regulation, science and politics. Before joining the “The Pink Sheet” he worked for Congressional Quarterly. Hobbs enjoys discussing BB-8 almost as much as he enjoys talking about 351(k).
Advertisement
Set Alert for Articles By M. Nielsen Hobbs

Latest From M. Nielsen Hobbs

Azar: International Regulatory Harmonization Will Create More Stable Generic Markets

HHS secretary tells AAM that "fundamental" changes require legislation, but "FDA and our peers are exploring new potential areas for alignment."
Generic Drugs Biosimilars

Azar: International Regulatory Harmonization Will Create More Stable Generic Markets

HHS secretary tells AAM that "fundamental" changes require legislation, but "FDA and our peers are exploring new potential areas for alignment."
Generic Drugs Biosimilars

Generic CEOs Need To Act Like Brand Execs, Association Head Says

AAM President Davis, a PhRMA veteran, says personal engagement – in addition to lobbying spending – is key to successful policy advocacy.

Biosimilars Generic Drugs

Generic CEOs Need To Act Like Brand Execs, Association Head Says

AAM President Davis, a PhRMA veteran, says personal engagement – in addition to lobbying spending – is key to successful policy advocacy.
Biosimilars Generic Drugs

Keeping Track Of Approvals: Cancer, Cancer, And A Two-Week Cancer Review

The latest drug development news and highlights from our US FDA Performance Tracker. 
Cancer Approvals

Keeping Track Of Breakthrough Therapy Designations: Depression, Headaches, Hepatitis

The latest developments in one of the US FDA's favorite pathways.

Review Pathway Drug Review
See All
Advertisement
UsernamePublicRestriction

Register